Dyne Therapeutics, Inc. · NASDAQ:DYN

Rhodes Jason P sold 777,451 Dyne Therapeutics, Inc. shares (Form 4)

Traded Jul 6 to Jul 7, 2026 · Filed Jul 8, 2026

From Jul 6 to Jul 7, 2026, Rhodes Jason P (Director) sold 777,451 Dyne Therapeutics, Inc. shares at an average US$22.97 for US$17.9M under a trading plan, leaving 2,962 shares. Filed Jul 8, 2026 (Form 4).

Sold
777,451 shares
Price
US$22.97 average (US$22.79 to US$23.62)
Value
US$17.9M
Holding after
2,962 shares (held indirectly)
Trading plan
Yes (Made under a plan set in advance)
Role
Director

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jul 6, 2026Common StockSale253,039US$22.794,223,448Indirect
Jul 6, 2026Common StockSale127,182US$22.791,217,537Indirect
Jul 6, 2026Common StockSale100,019US$22.79875,912Indirect
Jul 7, 2026Common StockSale124,379US$23.174,099,069Indirect
Jul 7, 2026Common StockSale29,587US$23.624,069,482Indirect
Jul 7, 2026Common StockSale62,543US$23.171,154,994Indirect
Jul 7, 2026Common StockSale14,844US$23.621,140,150Indirect
Jul 7, 2026Common StockSale49,193US$23.17826,719Indirect
Jul 7, 2026Common StockSale11,665US$23.62815,054Indirect
Jul 7, 2026Common StockSale5,000US$23.612,962Indirect

Source

View original at SEC

Related